Clinical trial NCT03984383: IL-33, Endocan and Endothelial Cells
Official title: Regulation of IL33, Endocan and Their Targets in Primary Human Endothelial Cells
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Endothelial Cell
Keywords: Endothelial cells
inflammation
endothelial dysfunction
IL-33
Endocan
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2019-06-13
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Lung-derived endothelial cells : every patient of more than 18 years undergoing lung cancer surgery in the department of thoracic surgery of the University Hospital of Lille.

Umbilical cord-derived endothelial cells : every patient of more than 18 years giving birth in the University Hospital of Lille in the absence of significant materno-foetal disorder (for example: meconium-stained amniotic fluid, chorioamniotis, placental thrombosis, eclampsia etc.) or of infection for HIV, VHB, VHC or if unknown status for HIV, VHB, VHC the day of the childbirth.

Brief summary: The study aims to investigate the inflammatory response of endothelial cells to various stimulations, in particular the production of IL33 and of endocan in response to allergens, agonists of microorganisms and pollutants.

For that purpose, this project attempts to set up a biological collection of lung and umbilical cord endothelial cells.

Lung endothelial cells are resected from a surgical specimen, resulting from a lung cancer surgery.

Umbilical cord-derived endothelial cells are taken from the umbilical cord collected during the delivery.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* signed consent
* Pregnant woman for umbilical cord-derive-endothelial cells

Exclusion Criteria:

* Age \< 18 years
* Refusal to participate to the study
* Endothelial cord-drived endothelial cells :

  * significant materno-foetal disorder (for example: meconium-stained amniotic fluid, chorioamnionitis, placental thrombosis, eclampsia etc.)
  * infection for HIV, VHB, VHC
  * unknown status for HIV, VHB, VHC the day of the childbirth.

Primary outcomes:
measure: change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.
timeFrame: change from Baseline at 48 hours after stimulation
Secondary outcomes:
measure: change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.
timeFrame: change from Baseline at 4 hours, 12h ours, 24 hours after stimulation
measure: change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.
timeFrame: change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
measure: change in IL33 protein concentration between stimulated and unstimulated primary human lung endothelial cells.
timeFrame: change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
measure: change in IL33 protein concentration between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.
timeFrame: change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
measure: change in the level of messenger RNA expressed as endocan / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.
timeFrame: change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
measure: change in the level of messenger RNA expressed as endocan / GAPDH ratio between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.
timeFrame: change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
measure: change in endocan protein concentration between stimulated and unstimulated primary human lung endothelial cells.
timeFrame: change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
measure: change in endocan protein concentration between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.
timeFrame: change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
Other outcomes:
Locations:
city: Lille
country: France
facility: Hop Calmette Chu Lille
Study officials:
affiliation: CHU Lille, Service de Pneumologie et Immuno-Allergologie
name: Cécile Chenivesse
role: PRINCIPAL_INVESTIGATOR
References: